Practices affEcting macitentan and selexipag patient persistence Rates utilizing pulmonary arterial hypertension clinical Site and patIent perSpecTives (PERSIST): a US qualitative analysis

Endothelial dysfunction is an underlying mechanism for the development of pulmonary arterial hypertension (PAH). Vascular endothelial growth factor (VEGF) and stromal cell-derived factor-1α (SDF) may help repair the dysfunctional endothelium and provide treatment for PAH.

One of the great diagnostic challenges for children with pulmonary arterial hypertension is the need for general anesthesia (GA) to enable successful right heart catheterization.

Recommended therapies for pulmonary arterial hypertension (PAH) have until recently targeted pathways with predominant effects of pulmonary vasodilation.1 The recent addition to treatment options of sotatercept, an activin signaling inhibitor which rebalances pro- and antiproliferative signaling, bolsters a longstanding goal of targeting pathogenic pulmonary vascular remodeling.